絞り込み

16638

広告

Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation.

著者 Adeboyeje G , Sylwestrzak G , Barron JJ , White J , Rosenberg A , Abarca J , Crawford G , Redberg R
J Manag Care Spec Pharm.2017 Sep ; 23(9):968-978.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (188view , 0users)

Full Text Sources

Medical

Miscellaneous

The use of non-vitamin K oral anticoagulants (NOACs) has increased steadily following marketing approval; however, their relative safety in nonvalvular atrial fibrillation (NVAF) patients in real-world clinical practice remains unclear.
PMID: 28854073 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード